Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesCardiologyAmbetter Nevada cardiac biomarker coverage update …
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.MP.156

    Cardiac Biomarker Testing (troponin, CK-MB, myoglobin)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.MP.156 alerts

    Get alerted when Policy CP.MP.156 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and coding stance for laboratory testing of cardiac biomarkers (troponin I/T, CK-MB, myoglobin) for evaluation of suspected acute myocardial infarction or myocardial injury for members of Ambetter Nevada (Centene-affiliated health plans).

    Policy Summary
    PayerAmbetter Nevada
    PolicyCardiac Biomarker Testing (troponin, CK-MB, myoglobin)
    Policy CodePolicy CP.MP.156
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionUse troponin I/T (CPT 84484) as the preferred cardiac biomarker and avoid CK-MB or myoglobin when troponin is ordered.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Troponin I/T preferredRecommended biomarker for suspected AMI
    CK-MB & myoglobin not necessaryNot medically necessary when evaluating suspected AMI

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    82553, 83874Codes listed as not medically necessary when billed with troponin
    AnnualPolicy review cadence

    Coverage Criteria — Cardiac Biomarker Testing

    Covered and Not Medically Necessary Tests

    Covered and not covered statements from policy:

    Preferred test for suspected AMI: Troponin I or T testing is medically necessary and the appropriate cardiac biomarker for evaluating suspected acute myocardial infarction (AMI) or myocardial injury due to other mechanisms.

    Policy statement I: troponin is the recommended primary diagnostic biomarker.

    Not medically necessary tests: Creatine kinase myocardial isoenzyme (CK-MB) and myoglobin testing are not medically necessary in the evaluation for suspected AMI because troponin is the recommended biomarker due to its superior sensitivity and accuracy.

    Policy statement II: CK-MB and myoglobin are considered obsolete for AMI evaluation when troponin testing is available.

    Per policy statement, CK-MB and myoglobin testing are not medically necessary for the evaluation of suspected acute myocardial infarction (AMI) when troponin testing is used. The policy specifies that troponin I or T is the medically necessary and appropriate cardiac biomarker for suspected AMI, and CK-MB/myoglobin do not provide additional diagnostic value in that context.

    Providers ordering cardiac biomarker testing for suspected AMI should use troponin I or T as the primary test. When troponin testing is performed, additional CK-MB or myoglobin assays are excluded from medical necessity determination and may be subject to denial per the policy.

    The policy explicitly lists CPT 82553 (Creatine kinase [CK], MB fraction only) and CPT 83874 (Myoglobin) as not medically necessary when billed with CPT 84484 (Troponin; I or T). Table 1 of the policy coding implications identifies these codes as not medically necessary in the setting where troponin testing is performed.

    Providers should reference the current CPT guidance when submitting claims, and recognize that prior authorization is not supported for CPT 82553 or CPT 83874 when they are ordered in conjunction with troponin testing, because the policy deems these tests unnecessary for AMI evaluation when troponin is available.

    Coding — CPT and Billing Guidance

    CPT codes referencedCPT
    84484Troponin; I or T
    82553Creatine kinase (CK), (CPK); MB fraction only
    83874Myoglobin

    Provider Actions — Authorization, Documentation, and Denial Risk

    Step Therapy

    Step therapy — Preferred initial test

    When ordering cardiac biomarker testing for suspected acute myocardial infarction (AMI), troponin (CPT 84484) is the recommended and preferred initial test. CK‑MB (CPT 82553) and myoglobin (CPT 83874) are considered obsolete for initial AMI evaluation and are not medically necessary when performed in addition to troponin testing.

    • Preferred initial test: CPT 84484 (Troponin I or T)
    • Do not order CK‑MB (CPT 82553) or Myoglobin (CPT 83874) as routine add‑ons to troponin for AMI evaluation
    Documentation Required

    Documentation expectations

    Document the clinical indication for troponin testing and, if CK‑MB or myoglobin are ordered, provide a clear, contemporaneous rationale for why troponin alone is insufficient or cannot be used. Include pertinent clinical findings (symptoms, timing of symptom onset, ECG results, serial testing plan) in the medical record to support the choice of tests.

    • Record presenting symptoms and timing relative to specimen collection

    Background — Clinical Rationale

    Cardiac troponins I and T are the preferred biomarkers for diagnosing acute coronary syndromes and AMI due to their high specificity and sensitivity and predominant expression in myocardium. The policy notes troponin assays are more accurate for detecting myocardial injury than older markers.

    Historically used biomarkers such as CK-MB and myoglobin are less sensitive and less specific than troponins and have been shown not to add diagnostic value when troponin testing is available. Guideline statements (ACC/AHA) and observational studies cited in the background support omission of CK-MB and myoglobin from routine AMI evaluation, documenting minimal incremental yield when troponin tests are performed.

    Definitions — Biomarker Descriptions

    Troponin I/T — definition and key properties as preferred biomarkers.
    DefinitionCardiac-specific proteins (troponin I and T) used as the preferred biomarkers for detection of myocardial injury and acute myocardial infarction due to high specificity and sensitivity.
    Clinical rolePrimary diagnostic biomarker for suspected acute myocardial infarction (AMI) and myocardial injury; recommended initial and preferred test.
    PerformanceHigher sensitivity and specificity for myocardial injury compared with older markers (CK‑MB, myoglobin).
    CodingReported as troponin; CPT 84484 (Troponin; I or T).
    CK-MB — definition and note on lower sensitivity/specificity relative to troponin.
    DefinitionCreatine kinase myocardial isoenzyme (CK‑MB), a historic serum marker of myocardial injury previously used in AMI evaluation.
    Policy Summary
    PayerAmbetter Nevada
    PolicyCardiac Biomarker Testing (troponin, CK-MB, myoglobin)
    Policy CodePolicy CP.MP.156
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionUse troponin I/T (CPT 84484) as the preferred cardiac biomarker and avoid CK-MB or myoglobin when troponin is ordered.
    SourceLink
    On This Page
    Coverage Criteria — Cardiac Biomarker TestingCoding — CPT and Billing GuidanceProvider Actions — Authorization, Documentation, and Denial RiskBackground — Clinical RationaleDefinitions — Biomarker Descriptions
  1. Include ECG findings and clinical suspicion for alternative diagnoses if troponin is not appropriate
  2. Detail why CK‑MB or myoglobin are needed in addition to troponin (if applicable)
    3. Denial Risk

    Denial risk for CK‑MB and myoglobin when billed with troponin

    When CPT 82553 (CK‑MB) or CPT 83874 (Myoglobin) are billed together with CPT 84484 (Troponin), these add‑on tests are subject to denial as not medically necessary. Prior authorization may be required if there is an atypical clinical justification; absence of documented rationale increases denial risk.

    • Denied codes when billed with troponin: CPT 82553, CPT 83874
    • Ensure documentation supports medical necessity if submitting these codes with CPT 84484
    • Prior authorization: obtain when clinical circumstances warrant CK‑MB or myoglobin despite troponin testing
    Prior Authorization

    Prior authorization guidance

    Prior authorization may be required for CK‑MB or myoglobin testing when billed with troponin. If seeking authorization, include the clinical rationale, relevant records (ECG, symptom onset timing, prior troponin results if applicable), and explain why troponin alone is inadequate.

    • Submit clinical justification and supporting documentation with prior authorization requests
    • Anticipate denial if prior authorization is not obtained or documentation is insufficient
    Diagnostic noteLess sensitive and less specific than cardiac troponins; generally does not add diagnostic value when troponin testing is available.
    Guideline stanceACC/AHA guidance and contemporary studies indicate CK‑MB is no longer necessary for acute coronary syndrome diagnosis since troponin assays became available.
    CodingCPT 82553 — Creatine kinase (CK), (CPK); MB fraction only.
    Myoglobin — definition and limited diagnostic value when troponin is available.
    DefinitionMyoglobin, an early‑released muscle protein formerly used in AMI evaluation.
    Diagnostic valueProvides limited additional diagnostic value when troponin testing is available and does not improve detection of AMI beyond troponin.
    Study evidenceClinical studies found neither myoglobin nor CK‑MB added diagnostic value when used with troponin testing.
    CodingCPT 83874 — Myoglobin.